Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  1.55 1.55% 101.30 1,480,496 13:26:21
Bid Price Offer Price High Price Low Price Open Price
101.00 101.30 102.00 98.45 99.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 591.92 135.73 13.57 7.6 743
Last Trade Time Trade Type Trade Size Trade Price Currency
13:26:24 AT 13 101.30 GBX

Indivior (INDV) Latest News

More Indivior News
Indivior Investors    Indivior Takeover Rumours

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
01/12/202009:39INDIVIOR THE PILL WITH NO CHEERS OR BEERS3,087
09/3/202010:34RB. de-merger 548
11/7/201907:29Johnson & Johnson court case oklahoma6
03/5/201909:16Judgement against insys2
31/7/201812:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:26:24101.301313.17AT
13:26:22101.3011.01AT
13:26:22101.301313.17AT
13:26:20101.301212.16AT
13:26:07101.301515.20AT
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
02/12/2020
08:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 99.75p.
Indivior Plc has a 4 week average price of 67p and a 12 week average price of 67p.
The 1 year high share price is 165.10p while the 1 year low share price is currently 32.90p.
There are currently 733,484,840 shares in issue and the average daily traded volume is 6,300,576 shares. The market capitalisation of Indivior Plc is £743,020,142.92.
27/11/2020
15:55
waldron: the motely fool Why did the Indivior share price crash 40% on Friday? Alan Oscroft | Friday, 27th November, 2020 | Drug manufacturer Indivior (LSE: INDV) had been soaring in 2020. In fact, as of market close Thursday, the Indivior share price had more than trebled so far this year. But that came to a crunching halt Friday with a whopping 40% crash. Indivior is still ahead more than 100% year-to-date, but what’s happened? Indivior was spun out of Reckitt Benckiser in 2014. And news emerged Friday that its parent has filed a $1bn lawsuit against it. The claim was, apparently, filed on 13 November. It involves an indemnity agreement between the two companies, signed at the time of their parting. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit! According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... In its announcement, Indivior said: “The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.“ More legal pressure for Indivior So we don’t have the details yet. But it’s telling that Indivior has been facing lawsuits related to its opioid dependency treatment Suboxone. The opioid dependency scandal is huge in the US. But it had seemed the matter was resolved after a previous US court case. On 13 November, Indivior told us that “a United States federal court in the Western District of Virginia has approved the agreement between the group and the U.S. Department of Justice and other government agencies that was announced on July 24. The court has also dismissed all charges that were returned by a grand jury in April 2019.” The company added that it “is pleased to put this matter behind it and move forward in a manner that provides certainty to its business.” That certainty has now been shattered. Thought it was all over? As part of the earlier agreement, Indivior had to pay $600m. Prior to that, in October, former CEO Shaun Thaxter had received a six-month jail sentence on charges relating to misrepresentation of the safety of Suboxone. Reckitt Benckiser had had to stump up $1,4bn to try to put it all behind it. And if that wasn’t enough, Indivior has been trying to fight off generic competitors who claim its patent has expired. That’s quite a story for a FTSE 250 company that, by Friday afternoon at least, has still seen its share price double in 2020. But what now? A tense wait Well, we’ll clearly need to wait and find out the details of the Reckitt Benckiser lawsuit. And how nice of Indivior to release the news on a Friday, to give investors time to stew over the weekend with no real hope of further information. Perhaps obviously, I wouldn’t buy now. But I generally wouldn’t invest in a company that’s been facing big legal problems anyway. And definitely not one connected with the US opioid dependency drama.
27/11/2020
14:28
the stigologist: INDV could sure do with some positive newsflow for a change ? Maybe on a potential new blockbuster drug in the pipeline Apropos of nothing the INDV2000 C4X3256 trial study completes December 1st htTps://clinicaltrials.gov/ct2/show/NCT04413552?term=c4x_3256&draw=2&rank=1
27/11/2020
11:44
steeplejack: Yes bizarre and amateurish.They've left the market hanging for further info.Given the claim was filed two weeks ago and its only just been picked up,you'd think the company might ring their old parent RB and ask for an explanation before screwing up their own share price.
23/11/2020
11:47
adrian j boris: (INDV) London Stock Exchange Share Price: 131.50 Bid: 131.30 Ask: 131.60 Change: 0.40 (0.31%)
14/11/2020
04:57
ariane: HOME > Latest > Indivior sinks as settlement confirmed Indivior sinks as settlement confirmed By Master Investor 13 November 2020 0 mins. to read Indivior sinks as settlement confirmed FTSE 250 pharmaceuticals firm Indivior (LON:INDV) saw its share price drop by 1.79% to 120.80p (as of 11:55 GMT) after a US federal court approved the agreement between the firm and the Department of Justice. Under the terms of the agreement, the company will pay $600 million over seven years and all charges brought by grand jury due to a subsidiary’s false statements will be dismissed. Management said they were pleased to put this matter behind them and to allow the company to move ahead with certainty.
02/11/2020
16:49
waldron: SURPRISED AT THE SPREAD Indivior (INDV) London Stock Exchange Share Price is delayed by 15 minutes Share Price: 107.20 Bid: 121.00 Ask: 98.25 Change: -3.10 (-2.81%) Spread: -22.75 (-18.80%)
24/9/2020
07:52
the grumpy old men: RNS Number : 9398Z Indivior PLC 24 September 2020 Indivior Takes Strategic Alignment Actions This release contains inside information. Slough, United Kingdom and Richmond, Virginia - September 24, 2020 - Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group's strategic priorities. These actions further consider Indivior's strategy and are intended to enhance the Group's commercial and R&D focus on the highest value opportunities, protect the Group's financial and operational flexibility in response to ongoing challenges posed by the COVID-19 pandemic and support the Group's long-term growth ambitions. Key actions Indivior is taking include: -- Reorganizing and reinvesting in the U.S. commercial function in-line with the continued penetration and growth of SUBLOCADE (R) (buprenorphine extended-release) Injection in the Organized Health System (OHS) channel and to facilitate expansion of PERSERIS (R) (risperidone) extended release injection into the OHS channel. This includes hiring and redirecting some employees to further our progress in this channel. -- Further focusing of R&D on post-marketing studies to support SUBLOCADE(R) and PERSERIS(R) and on the development of early-stage pipeline assets with the prioritization of INDV-2000 (selective Orexin-1 receptor antagonist) for the treatment of opioid use disorder and INDV-1000 (selective GABAb positive allosteric modulator) for the treatment of alcohol use disorder . -- Streamlining certain corporate functions and reducing discretionary spending, including suspending merit-based pay increases and lowering third-party expenditures. Comment by Mark Crossley, CEO of Indivior PLC: "We are taking the right strategic actions on organizational focus and cost management to better align our capabilities and resources with the Group's near- and medium-term priorities, while also supporting our long-term growth ambitions. While some of the expected savings will be reinvested to support the continued growth of SUBLOCADE(R) and PERSERIS(R) in the U.S. and targeted international geographies, we will retain a large portion of the expected savings to preserve the Group's flexibility through the COVID-19 pandemic. In addition, we are maintaining our core capabilities in addiction science to support drug discovery and development. These actions will result in a stronger organization with an improved cost position and the ability to continue to make investments to strengthen the global delivery platforms for SUBLOCADE(R) and PERSERIS(R). Critically, we are maintaining our strong commitment to integrity and compliance." "These actions, unfortunately, will impact our workforce as we are reorganizing and reallocating healthcare practitioner-facing resources in the U.S. toward Organized Health Systems, streamlining certain corporate functions and reducing discretionary expenses. While some teams will remain unchanged, others will be reduced in size to align with our strategic priorities. As always, we will look to support those that will be departing the Group." Based on the actions set out above, Indivior expects to reduce its operating expense base (SG&A plus R&D) by between $60m to $70m pre-tax in 2021 compared with its expected operating expense base in 2020 on an adjusted basis, excluding exceptional items. For reference, Indivior's H1 2020 adjusted operating expenses were $242m and the Group's FY 2020 Planning Assumptions include a slightly lower level of operating expenses on an adjusted basis in H2 2020 compared with H1 2020. A restructuring charge of approximately $6m will be booked as an exceptional item in the Q3 2020 financial results (which are scheduled to be reported on October 29, 2020). Actions associated with the key elements of the program are expected to be completed in the fourth quarter of 2020. Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30(th) as part of its H1 2020 results announcement, with the exception that SUBOXONE(R) Film share has continued to perform ahead of historical industry analogues (1) and Group expectations. (1) IMS Institute Report, January 2016, "Price Declines after Branded Medicines Lose Exclusivity in the U.S."
30/7/2020
15:23
waldron: Indivior in the red as opioid addiction treatment continues to lose market share to generics By BFN News | 08:54 AM | Thursday 30 July, 2020 Factsheet Indivior Plc Ord USD0.10 (INDV) Pharmaceutical company Indivior swung to a loss in the first half of the year after revenue declined by a third as the company's Suboxone film continue to lose market share to generics. For the six months ended 30 June, the company reported a pre-tax loss of $145m, compared with a profit of $163m on-year as revenue fell 33% to $303m. Suboxone film market share during H1 2020 averaged 22%, down from 38% on-year. Suboclade revenue jumped to $58m from $28m. Looking ahead, the company warned of a 'significant' reduction in Suboxone film revenue as a result of market share loss 'reaching historical industry analogues and negative channel mix.' Suboclade, meanwhile, was expected to see 'modest' growth in new patient enrollments compared with Q2 exit levels, it added. At 8:54am: (LON:INDV) Indivior Plc share price was +2p at 137.5p Story provided by StockMarketWire.com
17/6/2020
16:05
baddeal: SteeplejackBroker recommendations, buy hold etc are normally a function of where the actual share price is relative to their valuation target price. If the gap is small, as in this case with tp of 79p and actual around 70p then likely to be a hold recommendation. If gap is large likely to be a buy rating or sell if tp is below actual share price.... least this is how my old broker explained it to me once
06/6/2020
07:37
gibbs1: If we accept that the current INDV share price is valued realistcally until of course the court case is solved then the INVVY ADR in opinion seems a little overvalued Begs the question DO THEY KNOW SOMETHING WE DO NOT KNOW ME THINKS NO
Indivior share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201202 13:41:26